switching between glp-1 agonists ada - What is it? Efficacy and safety of GLP-1

Clinical uses of GLP-1: Obesity and its link to unhealthy aging Obesity is a significant modifiable contributor to unhealthy aging, accelerating the onset of CVDs, T2D, neurodegeneration, and certain cancers through chronic inflammation, oxidative stress, mitochondrial dysfunction, and disrupted insulin signaling

0.8% placebo), with total WL of 6.5% compared to 0.8% with placebo [97]

Prespecified subgroup analyses Subgroup analyses were conducted to examine variations in risk related to the desired outcomes among the GLP-1 RAs users

Semaglutide, with its 7-day half-life and once-weekly dosing, represents the longest-acting formulation currently available [23]

Concurrently, the Low Glycemic Index Treatment (LGIT), developed by Pfeifer and Thiele (2005), allows 4060 g of carbohydrates per day with a glycemic index below 50, achieving greater than 90% seizure reduction in 50% of patients in their initial series [97]